Cover Image


USTR Requests Comments on Foreign Nations’ Impact on U.S. Drug Prices

Estimated reading time: 3–5 minutes

USTR Requests Comments on Foreign Nations’ Impact on U.S. Drug Prices

On May 30, 2025, the Office of the United States Trade Representative (USTR) sent out a request for comments about foreign countries’ drug pricing rules and their effects on American patients.

This action follows President Biden’s Executive Order 14297, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” The order says that Americans should not have to pay more for prescription drugs because other countries pay less. It asks that Americans get the best price for prescription drugs, like the lowest price charged to other nations.

USTR is asking for information about any foreign act, policy, or practice that makes American patients pay too much for drug research and development. In particular, USTR is interested in any action that forces drug prices down in other countries, making the United States carry more of the costs.

How to Comment

Comments are due by June 27, 2025. To submit a comment, use the USTR portal at https://comments.ustr.gov/s/.

The comments should use docket number USTR-2025-0011.

If you cannot use the website, you can contact Deputy Assistant U.S. Trade Representative for Monitoring and Enforcement, Catherine Gibson, at 202.395.5725 or by email.

What to Include in Your Comment

USTR wants comments that name the foreign country or area, describe the act, policy, or practice, and tell why it may be unfair or discriminatory. Comments should also explain how this affects American patients and raises their share of drug research and development costs.

Anyone can send comments, including individuals, companies, and groups. The request repeats that parties are always welcome to send information about trade concerns.

Instructions for Submitting Comments

To submit online, go to the portal and choose the right docket. You do not need to create an account. Enter your contact details. Organizations must include their legal name and contact information.

There are options to mark parts of the comment as Business Confidential Information (BCI) or as Public. Mark any BCI as “BUSINESS CONFIDENTIAL” and highlight the confidential information. You must also send a public version without the confidential details.

If you need other ways to protect confidential business information, you can contact Catherine Gibson at 202.395.5725 to discuss options.

Submitted documents will be posted for public inspection, except for properly marked confidential information.

Contact for Questions

To discuss submission problems or for other questions, you may contact Catherine Gibson, Deputy Assistant U.S. Trade Representative for Monitoring and Enforcement, at 202.395.5725.

The request for comments was signed by Jennifer Thornton, General Counsel, Office of the United States Trade Representative.

Official notice number: 2025-09757.

For more details, visit the Federal Register at https://www.gpo.gov.


Legal Disclaimer

This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.